U.S. Patent Office Grants Interim Extension to VIVUS Inc.'s Patent for Adderall XR

Summary

The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a fourth one-year interim extension of the term of U.S. Patent No. 4,229,449, which covers VIVUS Inc.'s patent for the generic version of Adderall XR, a medication used to treat attention deficit hyperactivity disorder (ADHD).